Navigation Links
Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
Date:1/17/2008

Study in Overweight and Obese Type 2 Diabetics to Assess Safety and

Pharmacokinetics in addition to Specialized Secondary Endpoints

PLYMOUTH MEETING, Pa., Jan. 17 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced that dosing of subjects has begun in study MSI-1436C-103, the ascending single dose Phase 1 study of trodusquemine (MSI-1436), in overweight and obese type 2 diabetics. MSI-1436 is a novel therapeutic for the treatment of type 2 diabetes and obesity which works centrally and peripherally to regulate insulin and leptin receptor signaling through inhibition of its novel target enzyme PTP-1B.

Study 103 is similar in design to the previously completed Study 101 which was conducted in healthy obese and overweight volunteers. The current study will continue to expand the safety database for MSI-1436 and establish the pharmacokinetics of the drug in a population of type 2 diabetics who are poorly controlled on metformin. The study will also evaluate a range of secondary endpoints including short-term insulin/glucose control indices, glucose tolerance and evaluation of insulin sensitivity.

"We have achieved another important milestone in the development of MSI- 1436 and can now begin collecting data from obese type 2 diabetics," said Jack Armstrong, President and Chief Executive Officer of Genaera. "The unique mechanism of action provides MSI-1436 with the potential to impact two of the key pathologies of type 2 diabetes: insulin resistance and obesity. We anticipate that this clinical study will provide a first step in demonstrating the safety of MSI-1436 in obese and overweight type 2 diabetics and will help determine an optimal therapeutic dose for this population."

This r
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
6. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Enrollment Begins on Human PK Study for Medidur(TM) FA
9. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
10. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
11. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014 ... the U.S. commercial launch of its foot plating system ... Paragon 28.  The GORILLA TM R3CON PLATING SYSTEM ... the Monster TM & Mini-Monster TM Screw ... Comprised of 10 interchangeable subsystems, the GORILLA TM ...
(Date:9/22/2014)... Research and Markets ( ... the  "Global Remotes Market 2014-2018"  report to ... Remotes/remote controls are devices that ... such as smart TVs, set top boxes, ... distance. Remote controls are small wireless handheld ...
(Date:9/22/2014)... -- Final shortlist announced, winners to ... The second edition of the much-awaited VCCircle Healthcare Awards is round ... final nominations for the 2014 honours.  The names of ... 25 at The Taj Mahal Palace, Mumbai . The ... variety of qualitative and quantitative parameters - such as ...
Breaking Medicine Technology:Paragon 28, Inc. Launches the GORILLA(TM) R3CON PLATING SYSTEM 2Global Remotes Market 2014-2018 2Global Remotes Market 2014-2018 3Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3
... LYON, France, May 11, 2012 Mylan Inc. (Nasdaq: ... launched Atorvastatin Calcium Tablets, 10 mg, 20 mg, 40 ... the Netherlands and Ireland. Mylan has received marketing authorization ... its product immediately. Atorvastatin Calcium is the generic version ...
... /PRNewswire-iReach/ -- Electrochemical Oxygen Concepts (EO2™ ... chronic wound treatment device, announced it has been ... Federal Supply Schedule (FSS) contract, administered by The ... ® , a noninvasive, electrochemical low-dose tissue oxygenation ...
Cached Medicine Technology:Mylan Launches Generic Lipitor® in Five European Countries 2New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program 2New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program 3
(Date:9/22/2014)... (PRWEB) September 22, 2014 Airbus Helicopters ... industry Monday for their efforts to improve safety and ... Award and the Program of the Year award, both ... Air Medical Transport Conference Annual Community Awards. , ... with the Jim Charlson Aviation Safety Award, given annually ...
(Date:9/22/2014)... September 22, 2014 Starbrite Dental ... patients who require orthodontic work. Six-Month Smiles is designed ... deserve in a fast and effective way. , Many ... extremely daunting. Having to wear metal braces for several ... and spend time keeping the braces clean, is undesirable ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 United ... all of the federal mesh lawsuits ( http://www.meshinjurylawfirm.com/lawsuits/ ... have been consolidated for pretrial matters, issued an ... Corp. Pelvic Repair System Products Liability Litigation (United ... West Virginia; Case no. 2:12-md-02326)—requiring that four member ...
(Date:9/22/2014)... more and drink more , Study used smartphones to ... differ from past research on physical activity and exercise ... that on days when people exercise more -- typically ... , This is the only study to use smartphone ... activity and alcohol use. , "Monday through Wednesday people ...
(Date:9/22/2014)... and young adults at risk for sexually transmitted infections ... sexual behaviors, according to new recommendations from the U.S. ... million new sexually transmitted infections such as gonorrhea and ... people between 15 and 24 years old, according to ... Sept. 22 in Annals of Internal Medicine , ...
Breaking Medicine News(10 mins):Health News:Airbus Helicopters Inc. Honors Leaders in Air Medical Industry 2Health News:Airbus Helicopters Inc. Honors Leaders in Air Medical Industry 3Health News:Starbrite Dental Introduces Six-Month Smiles 2Health News:Federal Court Sets Trial Date for Boston Scientific Vaginal Mesh Cases in Florida, the Rottenstein Law Group LLP Reports 2Health News:We drink more alcohol on gym days 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 3
... statement,is being released by Sr. Carol Keehan, DC, ... Association of the United States (CHA):, The ... provided,today by the Holy See,s Congregation for the ... administered nutrition and,hydration to patients in a persistent ...
... Pharmaceuticals,Inc. (Nasdaq: AMLN ) management will be presenting ... Annual Meeting of the European,Association for the Study of ... PT / 1:30 p.m. CET local time in Amsterdam, ... recordings will be made,available following the event. The webcast ...
... Sept. 13 (HealthDay News) -- It,s under your movie seat ... , But relief may be in sight. This week, researchers ... chewing gum at the BA Festival of Science in York, ... clothes, hair and sidewalks, and preliminary tests indicate that it ...
... Mich., Sept. 14 Stryker,Corporation (NYSE: SYK ) ... conference: September 25, 2007 - 4:30 p.m. Eastern ... York, New York A simultaneous webcast of the ... http://www.stryker.com via the For Investors page. The,presentation for ...
... Sept. 14 Mylan Laboratories Inc.,(NYSE: MYL ... Lacerca to the,position of Senior Vice President and ... from Bristol-Meyers Squibb where she was,Director of Compliance ... she was responsible for all compliance-related matters in ...
... WASHINGTON, Sept. 14 - The successful,implementation of electronic ... program $1.2 million per month according to a ... and increased quality,demonstrated in Mississippi reinforces the importance ... Management Association,(PCMA) said today., "The state of ...
Cached Medicine News:Health News:Comment Regarding Congregation for the Doctrine of Faith Clarification Concerning Nutrition and Hydration for Patients in a Persistent Vegetative State 2Health News:Stryker to Present at Investor Conference 2Health News:Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer 2Health News:E-Prescribing Saving Mississippi Medicaid $1.2 Million Per Month 2
... Graham-Field has been developing diverse ... 58 years. Our medical-surgical products ... for innovation, quality and customer ... include the Labtron® line of ...
... spill-proof design and effective output, even when ... medical nebulizers are free-standing for easy preparation., ... available., ,All Portex® medication nebulizer products ... feature consistently fine misting and the efficient ...
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
... with metered dose inhalers., ,ACE ensures ... MDI canisters. Its versatile design allows it ... in conjunction with an endotracheal airway or ... ACE may also be used in conjunction ...
Medicine Products: